Activity of the janus kinase inhibitor Ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

David E. Spaner, Guizhei Wang, Lindsay McCaw, Yanmei Li, Patricia Disperati, Mary-Ann Cussen, and Yonghong Shi

Disclosures: This work was supported by grants from the Leukemia and Lymphoma Society of Canada (LLSC) and Novartis Canada.

Contributions: DS designed the research, analyzed the data, and wrote the paper. YS, LM, GW, and YL helped design and perform experiments. MC was responsible for maintaining clinical data. PD provided patients for the trial.